{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:39:49Z","timestamp":1747190389220,"version":"3.40.5"},"reference-count":17,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DIAVEIN SAS"},{"name":"Rue de la Chapelle"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Hematology"],"published-print":{"date-parts":[[2021,2,4]]},"abstract":"<jats:p>Background. Vaso-occlusive crisis (VOC) is the primary cause of hospitalization in patients with sickle cell disease. Treatment mainly consists of intravenous morphine or nonsteroidal anti-inflammatory drugs (NSAIDs), which have many dose-related side effects. The question arises as to whether vascular electrical stimulation therapy (VEST) could be effective or not on VOCs. Objective. To measure the effectiveness and safety of VEST in reducing the median time spent in severe VOC. Methods. We conducted a phase II, single blinded, randomized, controlled, triple-arm, comparative trial. We included thirty (30) adult patients with severe vaso-occlusive crisis. The study arms were divided as follows: our control group (group 0) constituted of 10 patients followed with conventional therapy (Analgesics\u2009+\u2009Hydration\u2009+\u2009NSAIDs), while 20 patients were divided equally into two interventional arms\u201410 patients followed with VEST\u2009+\u2009Analgesics\u2009+\u2009Hydration (group 1) and the other 10 patients followed with VEST\u2009+\u2009Analgesics\u2009+\u2009Hydration\u2009+\u2009NSAIDs (group 2). The primary efficacy endpoint was median time to severe crisis elimination. The secondary end points were median time to end-of-crisis, median tramadol consumption, progress of the haemoglobin level over 3 days, side effects, and treatment failure. Results. The age ranged from 14 to 37 years, including 23 women. We noted a beneficial influence of the VEST on the median time to severe crisis (VAS greater than 2) elimination; 17 hours (group 1) against 3.5 hours (group 2) <jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>p<\/a:mi>\n                        <a:mo>=<\/a:mo>\n                        <a:mn>0.0166<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula> and 4 hours (group 3) with <jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>p<\/c:mi>\n                     <\/c:math>\n                  <\/jats:inline-formula> value\u2009=\u20090.0448. Similar significant results were obtained on the diminution of total duration of the crisis (VAS over 0) and median tramadol consumption in patients in the interventional arms. Conclusion. These statistically significant results in the interventional arms suggest that VEST could be an alternative treatment of VOC in sickle cell patients.<\/jats:p>","DOI":"10.1155\/2021\/1373754","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T04:35:23Z","timestamp":1612499723000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Tolerance of Vascular Electrical Stimulation Therapy in the Management of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: A Phase II Single-Centre Randomized Study in Ivory Coast"],"prefix":"10.1155","volume":"2021","author":[{"given":"Ren\u00e9e-Paule","family":"Botti","sequence":"first","affiliation":[{"name":"Clinical Hematology Unit, CHU de Yopougon, BP 3709 Abidjan 08, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sie Sa\u00efda","family":"Bokoum","sequence":"additional","affiliation":[{"name":"Clinical Hematology Unit, CHU de Yopougon, BP 3709 Abidjan 08, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3009-2765","authenticated-orcid":true,"given":"Etienne","family":"L\u2019Hermite","sequence":"additional","affiliation":[{"name":"Diavein SAS, 227 Rte de La Chapelle, 74540 St Felix, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dohoma Alexis","family":"Silue","sequence":"additional","affiliation":[{"name":"Clinical Hematology Unit, CHU de Yopougon, BP 3709 Abidjan 08, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boidy","family":"Kouakou","sequence":"additional","affiliation":[{"name":"Clinical Hematology Unit, CHU de Yopougon, BP 3709 Abidjan 08, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Anastasie","family":"Bognini","sequence":"additional","affiliation":[{"name":"Clinical Hematology Unit, CHU de Yopougon, BP 3709 Abidjan 08, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge Arnaud","family":"Agoua","sequence":"additional","affiliation":[{"name":"Clinical Hematology Unit, CHU de Yopougon, BP 3709 Abidjan 08, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-3509","authenticated-orcid":true,"given":"Edgar","family":"Mandeng Ma Linwa","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rom\u00e9o","family":"Ayemou","sequence":"additional","affiliation":[{"name":"Clinical Hematology Unit, CHU de Yopougon, BP 3709 Abidjan 08, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouassi Gustave","family":"Koffi","sequence":"additional","affiliation":[{"name":"Clinical Hematology Unit, CHU de Yopougon, BP 3709 Abidjan 08, Abidjan, C\u00f4te d\u2019Ivoire"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"issue":"22","key":"1","first-page":"31","article-title":"L\u2019Africain Noir et son hemoglobine","volume":"91","author":"R. Cabannes","year":"1991","journal-title":"Gaz Medicale"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61229-x"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1590\/s1984-82502012000400009"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199709113371107"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1160\/th06-12-0718"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-227330"},{"issue":"11","key":"7","first-page":"693","article-title":"Essai th\u00e9rapeutique du K\u00e9toprof\u00e8ne (Profenid) dans le traitement des crises douloureuses de la dr\u00e9panocytose","volume":"37","author":"A. Sangare","year":"1990","journal-title":"M\u00e9decine Afr Noire"},{"issue":"2","key":"8","article-title":"Essai th\u00e9rapeutique de la Buprenorphine (Temgesic) dans le traitement des crises douloureuses drepanocytaires","volume":"45","author":"A. Sangare","year":"1992","journal-title":"M\u00e9decine Afr Noire"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01254-2"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1159\/000097690"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(92)90668-z"},{"key":"12"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4202"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5541"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5756"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.235"},{"key":"17","article-title":"Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease","volume":"8","author":"S. Pal","year":"2020","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2021\/1373754.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2021\/1373754.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2021\/1373754.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T12:58:21Z","timestamp":1613825901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/ah\/2021\/1373754\/"}},"subtitle":[],"editor":[{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":17,"alternative-id":["1373754","1373754"],"URL":"https:\/\/doi.org\/10.1155\/2021\/1373754","relation":{},"ISSN":["1687-9112","1687-9104"],"issn-type":[{"type":"electronic","value":"1687-9112"},{"type":"print","value":"1687-9104"}],"subject":[],"published":{"date-parts":[[2021,2,4]]}}}